Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that interim results from an
ongoing Phase II clinical trial of Puma's investigational drug PB272
(neratinib) were presented at the 2014 CTRC-AACR San Antonio Breast
Cancer Symposium (SABCS) that is currently taking place in San Antonio,
Texas. The trial was supported by the National Comprehensive Cancer
Network®, ASCO's Young Investigator Award,more...